The Hikma Court correctly held that a generic manufacturer should not be liable for induced patent infringement if it carves patented uses out of its label. FDA can navigate Hikma’s aftermath without ...
Share on Pinterest Federal regulators have agreed to review a Swiss pharmaceutical company’s applications for two cheaper generic versions of Zepbound and Mounjaro. MK Photo/Alamy Stock Photo Federal ...
Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, infectious disease, telemedicine, mental health and health technology. Carley ...
The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...
Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...
WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...
Most disputes between pharmaceutical companies and generic drugmakers end in settlements. Five years of class-action litigation over a Takeda Pharmaceutical gastrointestinal drug culminated this week ...
Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...
The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...
Americans are unlikely to see generic versions of semaglutide — the active ingredient in Novo Nordisk’s Ozempic and Wegovy — until at least the end of 2031, according to a May 13 NBC News report. Novo ...
Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...
The chief executive of generic-drug maker Sandoz SDZ2.26%increase; up pointing triangle Group expects the market for unbranded versions of popular weight-loss medicines to be big. Just how big, though ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results